Considering the dependence of VPA effect on PI3K signaling activation, PI3K inhibitors should not be administered as anti-cancer drugs in patients with pancreatic cancer undergoing NK cell-mediated adoptive immunotherapy. The gene discussed is PIK3CA; the disease is cancer.